full

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.

CME information and select publications here

About the Podcast

Show artwork for Oncology Today with Dr Neil Love
Oncology Today with Dr Neil Love
A Research To Practice Podcast for Oncology Clinicians

Listen for free